a.org/","@type":"MusicRecording","@id":"https://play.anghami.com/song/1209795571","url":"https://play.anghami.com/song/1209795571","name":"Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma","description":"The Lancet Haematology in conversation with · Episode · 2025","datePublished":"2025-04-28","image":"https://artwork.anghcdn.co/webp/?id=202770345&size=640","byArtist":{"@type":"MusicGroup","name":"The Lancet Group"},"inAlbum":{"@type":"MusicAlbum","name":"The Lancet Haematology in conversation with"},"potentialAction":{"@type":"ListenAction","target":[{"@type":"EntryPoint","urlTemplate":"https://play.anghami.com/song/1209795571?autoplay=true","actionPlatform":["http://schema.org/DesktopWebPlatform","http://schema.org/IOSPlatform","http://schema.googleapis.com/GoogleAudioCast","http://schema.googleapis.com/GoogleVideoCast"]},"android-app://com.anghami/song/ 1209795571?autoplay=true"],"expectsAcceptanceOf":{"@type":"Offer","category":"free"}}}1c:T4aa,

Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.

Read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhae

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancet

Michael Northend on early rituximab mono...